BlackRock’s CG Oncology CGON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$450M Buy
6,347,335
+91,047
+1% +$6.69M 0.01% 1264
2026
Q2
$445M Buy
6,256,288
+1,192,108
+24% +$77.9M 0.01% 1305
2026
Q1
$343M Buy
5,064,180
+220,938
+5% +$12.5M 0.01% 1353
2025
Q4
$201M Buy
4,843,242
+256,728
+6% +$10.6M ﹤0.01% 1684
2025
Q3
$185M Buy
4,586,514
+130,091
+3% +$3.78M ﹤0.01% 1707
2025
Q2
$116M Buy
4,456,423
+101,363
+2% +$2.44M ﹤0.01% 1948
2025
Q1
$107M Buy
4,355,060
+293,930
+7% +$8.27M ﹤0.01% 1948
2024
Q4
$116M Buy
4,061,130
+490,203
+14% +$16.8M ﹤0.01% 1989
2024
Q3
$135M Buy
3,570,927
+1,594,857
+81% +$55.9M ﹤0.01% 1909
2024
Q2
$62.4M Sell
1,976,070
-542,480
-22% -$18.8M ﹤0.01% 2288
2024
Q1
$111M Buy
+2,518,550
New +$103M ﹤0.01% 2002

Other funds holding CGON

BlackRock's CGON Position: Q3 2026 in Review

BlackRock increased its CG Oncology (CGON) stake by 1.5% in Q3 2026, buying an estimated $6.69M and bringing the position to 6,347,335 shares worth $450M. The position accounts for 0.01% of the portfolio, ranked #1264.

BlackRock first reported a position in CGON in Q1 2024 and has held it in 11 quarters since. 233 funds tracked by Wall St. Rank hold CGON as of Q3 2026.

  • BlackRock held 6,347,335 shares of CG Oncology worth $450M as of Q3 2026.
  • BlackRock bought 91,047 CG Oncology shares in Q3 2026, an estimated $6.69M.
  • CG Oncology made up 0.01% of BlackRock's portfolio in Q3 2026, its #1264 holding.
  • BlackRock first reported a position in CG Oncology in Q1 2024 and has held it in 11 quarters since.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.